Form 4: Surmodics Executive Sells Shares to Cover Tax Obligations

Sentiment:

SEC Form 4 Filing


A Surmodics executive sold 1,030 shares of common stock to cover tax obligations related to stock awards.

Summary

  • Gordon S. Weber, a Senior Vice President at Surmodics, sold 1,030 shares of common stock on November 30, 2024.
  • The sale was executed at a price of $39.45 per share.
  • This transaction was to cover tax obligations related to stock awards.
  • Following the transaction, Weber directly owns 21,708 shares of Surmodics stock.
  • The reported holdings include 324 shares acquired through the Employee Stock Purchase Plan for the phase ending 2/29/24 and 349 shares acquired for the phase ending 8/31/24.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction by an executive to manage their stock holdings and tax obligations. It is neither positive nor negative for the company's outlook.

Industry Context

This is a routine transaction for executives to manage their tax obligations related to stock-based compensation. It is common for executives to sell shares after vesting or exercising options.

Comparison to Industry Standards

  • Executive stock sales are a common occurrence in publicly traded companies, particularly around vesting periods or to cover tax liabilities.
  • The sale by Gordon S. Weber is consistent with standard practices for executives managing their personal finances and stock holdings.
  • Similar transactions are regularly reported by executives at comparable companies in the medical device industry.

Stakeholder Impact

  • The transaction has a minimal impact on shareholders as it is a routine sale by an executive.
  • There is no direct impact on employees, customers, suppliers, or creditors.

Key Dates

DateDescription
2024-02-29End date of a phase of the Employee Stock Purchase Plan where 324 shares were acquired.
2024-08-31End date of a phase of the Employee Stock Purchase Plan where 349 shares were acquired.
2024-11-30Date of the stock sale transaction.
2024-12-03Date the Form 4 was signed.

Keywords

Surmodics, insider trading, stock sale, executive, Form 4, SRDX, Gordon S. Weber, employee stock purchase plan

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.